Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
09:41am, Monday, 11'th May 2026
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
07:30am, Monday, 11'th May 2026
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Thursday, 07'th May 2026
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:12am, Wednesday, 06'th May 2026
One of these stocks plummeted 49% on Tuesday.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 05'th May 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st May 2026
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing
03:13pm, Wednesday, 29'th Apr 2026
Intellia Therapeutics (NASDAQ: NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioed
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
07:00am, Wednesday, 29'th Apr 2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Cathie Wood just made a massive bet on these two top AI stocks
06:27am, Wednesday, 29'th Apr 2026
While the heyday of Cathie Wood's investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and un
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
02:06pm, Tuesday, 28'th Apr 2026
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.
Intellia Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 27'th Apr 2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Wall Street on Edge Ahead of Next U.S.-Iran Development
12:05pm, Monday, 27'th Apr 2026
Stocks are lower across the board, as investors await the latest U.S.-Iran developments and monitor oil prices
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
10:07am, Monday, 27'th Apr 2026
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at tr
Stock Futures Subdued by Geopolitical Uncertainty
09:11am, Monday, 27'th Apr 2026
Stock futures are struggling this morning as investors await Magnificent Seven earnings and the Fed meeting
